Canadian contract research organisation BRI Biopharmaceutical Research is using the Thermo Scientific Watson LIMS (laboratory information management system) to help manage the bioanalytical and analytical chemistry data generated by its principal laboratories.
The system includes LC/MS/MS assays of specialised biomarkers, nucleotides, peptides and synthetic small molecule drugs in support of GLP PK/TK pre-clinical studies and clinical phase I to IV trials. It will also be instrumental in managing BRI's in vivo and in vitro DM/PK/ADME studies.
BRI says the Watson LIMS will ensure timely delivery of quality results to clients and improve the internal operational efficiency and profitability of the company.
"Watson LIMS is a critical tool in our laboratory infrastructure that enables us efficiently to manage a wide variety of sponsor protocols and provides for the consistent and reliable delivery of data that is required for GLP and FDA submission requirements," said Clara Faan, vice president of operations at BRI Biopharmaceutical.
Thermo Scientific Watson LIMS is a highly specialised, protocol-driven system for drug metabolism and pharmacokinetic (DMPK) studies. It is used by 18 of the top 20 global pharmaceutical companies and leading contract research organisations worldwide.